APTX - Aptinyx Inc.
| Previous Close | 3.1500 |
| Open | 3.1794 |
| Bid | 3.1800 x 800 |
| Ask | 3.2000 x 1000 |
| Day's Range | 3.1150 - 3.2200 |
| 52 Week Range | 2.6100 - 26.7400 |
| Volume | 19,904 |
| Avg. Volume | 104,023 |
| Market Cap | 107.102M |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.7240 |
| Earnings Date | Nov 11, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 11.00 |
- ACCESSWIRE
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Aptinyx Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / November 19, 2019 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Aptinyx Inc. ...
- ACCESSWIRE
FIRST FIRM TO INVESTIGATE: The Schall Law Firm Announces it is Investigating Claims Against Aptinyx Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / November 18, 2019 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Aptinyx Inc. ...
- ACCESSWIRE
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aptinyx Inc. - APTX
NEW YORK, NY / ACCESSWIRE / November 15, 2019 / Pomerantz LLP is investigating claims on behalf of investors of Aptinyx Inc. ("Aptinyx" or the "Company") (NASDAQ:APTX). Such investors ...
- GlobeNewswire
Aptinyx to Present at Upcoming Investor Conferences
Aptinyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of proprietary synthetic small molecules for the treatment of brain and nervous system disorders. The company has three product candidates in clinical development in central nervous system indications, including chronic pain, post-traumatic stress disorder, and cognitive impairment associated with Parkinson’s disease. Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995.
- Zacks
Aptinyx Inc. (APTX) Reports Q3 Loss, Tops Revenue Estimates
Aptinyx Inc. (APTX) delivered earnings and revenue surprises of 4.35% and 2.86%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Aptinyx Reports Third Quarter 2019 Financial Results and Highlights
Initiated two Phase 2 studies of NYX-2925 in chronic pain conditions On track to have four Phase 2 studies ongoing by year end across pipeline of CNS product candidates.
- GlobeNewswire
Aptinyx Initiates Two Phase 2 Studies of NYX-2925 in Patients with Chronic Centralized Pain Conditions
Aptinyx Inc. (APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the initiation of two Phase 2 studies evaluating NYX-2925 for the treatment of painful diabetic peripheral neuropathy (DPN) and for the treatment of fibromyalgia. NYX-2925 is a novel NMDA receptor modulator that has been granted Fast Track designation by the U.S. Food and Drug Administration.
- Simply Wall St.
How Much Of Aptinyx Inc. (NASDAQ:APTX) Do Insiders Own?
A look at the shareholders of Aptinyx Inc. (NASDAQ:APTX) can tell us which group is most powerful. Insiders often own...
- Zacks
Earnings Preview: Aptinyx Inc. (APTX) Q3 Earnings Expected to Decline
Aptinyx Inc. (APTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire
Aptinyx to Report Third Quarter 2019 Financial Results on Tuesday, November 12, 2019
EVANSTON, Ill., Nov. 05, 2019 -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and.
- GlobeNewswire
EQUITY ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Aptinyx Inc.
NEW YORK, Oct. 29, 2019 -- Levi & Korsinsky reminds investors that it has commenced an investigation of Aptinyx Inc. (“Aptinyx” or “the Company”) (NASDAQ: APTX) concerning.
- GlobeNewswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aptinyx Inc. - APTX
Pomerantz LLP is investigating claims on behalf of investors of Aptinyx Inc. (“Aptinyx” or the “Company”) (APTX). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. The investigation concerns whether Aptinyx and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
- ACCESSWIRE
Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Aptinyx Inc. (APTX)
NEW YORK, NY / ACCESSWIRE / October 29, 2019 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Aptinyx Inc. ("Aptinyx" or the "Company") ...
- GlobeNewswire
Kaskela Law LLC Announces Investigation of Aptinyx Inc. (APTX) on Behalf of Investors
PHILADELPHIA, Oct. 28, 2019 -- Kaskela Law LLC is investigating Aptinyx Inc. (“Aptinyx” or the “Company”) (Nasdaq: APTX) on behalf of the Company’s investors. Aptinyx.
- GlobeNewswire
Aptinyx Announces Results of Phase 2 Fibromyalgia Study of NYX-2925 Have Been Selected for Late-Breaking Presentation at the American College of Rheumatology Annual Meeting
EVANSTON, Ill., Oct. 28, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the results of a Phase 2 study of NYX-2925 in patients with fibromyalgia have been selected for a late-breaking poster presentation at the American College of Rheumatology Annual Meeting. The study was conducted in collaboration with the Chronic Pain and Fatigue Research Center at the University of Michigan Medical School and the Women's Health Research Program at University of Cincinnati College of Medicine.
- ACCESSWIRE
SHAREHOLDER NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Aptinyx Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / October 25, 2019 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Aptinyx Inc. ("Aptinyx" ...
- ACCESSWIRE
2018 SHAREHOLDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against Aptinyx Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / October 23, 2019 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Aptinyx Inc. ("Aptinyx" ...
- ACCESSWIRE
INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Aptinyx Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / October 22, 2019 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Aptinyx Inc. ("Aptinyx" ...
- ACCESSWIRE
URGENT SHAREHOLDER NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Aptinyx Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / October 18, 2019 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Aptinyx Inc. ("Aptinyx" ...
